CVKD CVKD
Company Profile ↓Company Overview
CVKD (CVKD) is a publicly traded company listed on with a market capitalization of $4.58M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -77.75% |
| 6 Months: | -68.44% |
| 3 Months: | -68.99% |
| 1 Month: | -37.97% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)31.43 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 86.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -170.52K | -482.35K | -972.79K | -4.20M | -1.03M | -1.14M | -1.76M | -2.47M | -2.46M | -3.93M | -3.73M | -2.73M | -2.51M |
| Net Income | -176.65K | -502.14K | -1.03M | -5.17M | -1.00M | -1.04M | -1.66M | -2.39M | -2.41M | -3.85M | -3.67M | -2.69M | -2.50M |
| Diluted EPS | -0.02 | 0.07 | -0.13 | -0.48 | -0.09 | -1.01 | -1.56 | -2.24 | -2.18 | -2.09 | -1.87 | -1.31 | -1.04 |
| R&D Expense | - | - | 56.39K | 3.24M | 240.96K | 243.95K | 629.02K | 1.25M | 784.65K | 1.67M | 1.08M | 688.47K | 771.51K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Income | -2.70M | -7.63M | -10.96M | -13.46M |
| Net Income | -6.71M | -8.36M | -10.65M | -13.24M |
| Diluted EPS | -0.85 | -9.29 | -8.73 | -6.64 |
| R&D Expense | 392.86K | 4.08M | 4.21M | 4.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 778.17K | 8.52M | 10.12M | 4.33M |
| Current Assets | 727.60K | 8.49M | 10.11M | 4.32M |
| Cash & Equivalents | 32.59K | 8.40M | 10.02M | 4.01M |
| Inventory | - | - | - | - |
| Receivables | - | 37.25K | 38.15K | 5.10K |
| Total Liabilities | 6.33M | 826.88K | 2.68M | 1.59M |
| Current Liabilities | 1.33M | 826.88K | 2.68M | 1.59M |
| Long Term Debt | 553.34K | - | - | - |
| Total Debt | 640.71K | 21.35K | 0 | - |
| Total Equity | -5.55M | 7.69M | 7.44M | 2.74M |
| Shares Outstanding | 775.64K | 868.18K | 1.78M | 2.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.20M | -3.53M | -7.36M | -12.60M |
| Investing Cash Flow | -2.28K | -3.25K | -6.54K | -5.10K |
| Financing Cash Flow | 1.24M | 11.90M | 8.98M | 6.60M |
| Capital Expenditure | -2.28K | -3.25K | -6.54K | -5.10K |
| Free Cash Flow | -1.21M | -3.53M | -7.36M | -12.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 121.0% | -108.6% | -143.2% | -483.3% |
| ROCE % | 485.6% | -99.2% | -147.3% | -491.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CVKD
Discipline and Rules-Based Execution in CVKD Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOYVJjRVE2ckh3MzhWUW1lelZqYjRvMGRSQ05YRXFzRE83OHU3V3NoQl9TS196TjFsUGJGQVpvMGFKZFNEMDJEUVYwRFFxbXRZa0FoMlhpVFJvNmFxdVdKeGhQZENlTi1vbXgzZU9uREdqUExndXVoemp3NHBCTGN5VHo2TjlhWVlWMFJpYl…
CAD-1005 Phase 2 Data Show >25% Absolute Reduction in Thrombotic Events - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQSDRMMG9mZUR6cmUtQWxhYTM0ODlZWmJFWE9Nb1JpblkzaTZDcUd0bzRHb0dXSGJJWjc2andXQVRoM0xXMzhVcXVzbVpobUs1c09PRUxFU3BFMXJ3WWV2V3N5em9wR1ZxeWZweVFOYW5yTm1OVUg4NmVUQVowci1jSmU4NnZ3UFJ6cG1kTD…
Nasdaq, S&P 500, Dow Futures Pause After Strong H1 Rally Ahead Of Payrolls: Why NKE, TSLA, NIO, MU, LUNR, CVKD Are In Focus - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxPdkRBQVAtdmNlMnhhZ1lUMDU0R0l2YUU5aks1MWwzRW1yblNqRmtLb2VkbXFZalZSd0VsSy1KbTNsSGwwX2h1NlpwNDJ0cmdFelhET3NneFRVZlItTktYcldSd3pKbTU2M3F0Ql9pY2ZKbjNlTG1kbjVuRktEZUItaU1xaDdYdFhGc1lXdy…
CVKD Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1tdzZ2MXVYMGZ5T21lZWRFYWNJSUtkRDZWU1FxYkY4ZUlHR29XeVI0TVFEME9WbHpoT0tsSDFSaVFsUllNWV85N1hHdmlDTURVanQ5ZElVaUU1YW9QVHVfU05BZDJLLXZETmNkd1c3SkZtNUJMSUhmSlB3?oc=5" target="_blank">CVK…
Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQcGY4dmJrWXBHUEVvcmFKV1h2eFljbkFMeEV4YW5wN0Y4Z241c2tuMDA3MDFvYVRiektPMC1HRjhiSERPbjN3X2tibzhTQXZDbUNRMEJHLUNEZm14OVl1ZVd3S2lMVnBCclNoR0lJR25ydWE2ekNZQ1VtZlpNVFk5YmxYQnBXQXBHX19US1…
Cadrenal Therapeutics, Inc. SEC Filing (Aug 3, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOS3BDN2ZZbzk0dXJucWFzOW9mRnZWbjMtYU1ET09uMVhnUXd0T2VfV1MxQkN4REFiSkVDcjgycTRFTTBCZW1wd1lqLUVFMV9BVHBDRnJaZU9yQWV4TEtFQnhVVG9VaUVHUmI4X0FCSnVkREtxdUt5c2o2czQyVXhaY2RHT2xGUm5zNFVyYX…
CVKD — Frequently Asked Questions
What is the current share price of CVKD?
As of 2026-08-05 17:25 PDT, CVKD trades at $1.96 on NASDAQ/NYSE. Its 52-week range is $1.96 to $14.20.
What is the market capitalisation of CVKD?
CVKD has a market capitalisation of $4.58M on NASDAQ/NYSE.
What is the P/E ratio of CVKD?
CVKD trades at a trailing price-to-earnings (P/E) ratio of -0.30. Its price-to-book (P/B) ratio is 1.67.
Is CVKD a good stock to buy?
This page provides a data-driven analysis of CVKD, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.